NEO Neogenomics Inc.
2,638
$14.80
$0.19
(1.27%)
| Watchers | 2,638 |
| 52-Wk Low | $11.03 |
| 52-Wk High | $21.22 |
| Market Cap | $1.89B |
| Volume | 639,983.00 |
| 52-Wk High | $21.22 |
| 52-Wk Low | $11.03 |
Latest Ratings for NEO
DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsEqual-Weight Feb 2022NeedhamMaintainsBuy Feb 2022Raymond JamesMaintainsOutperform
View More Analyst Ratings for NEO...
NeoGenomics, Inc. (NASDAQ: NEO) (the Company), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately. Warren Stone has been promoted...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its first quarter 2024 financial results on Tuesday, April 30, 2024. Company...
This is a signal that NEO's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...
Shares of NeoGenomics, Inc. (NASDAQ:NEO Get Free Report) have earned a consensus rating of Moderate Buy from the eleven ratings firms that are covering the stock, Marketbeat...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, alongside research collaborators, will present key findings from 11 abstracts at the American Association for Cancer...
This price move could indicate a change in the trend, and may be a sell signal for investors...